Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Trial of Escalating Dose of RAD001 in Combination With PKC412 in Patients With Relapsed, Refractory or Poor Prognosis AML or MDS

NCT00819546 is registered in ClinicalTrials.gov with Richard Stone, MD as lead sponsor.

NCT NCT00819546
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00819546 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Trial of Escalating Dose of RAD001 in Combination With PKC412 in Patients With Relapsed, Refractory or Poor Prognosis AML or MDS
Lead sponsor
Richard Stone, MD
Phase
Phase 1
Overall status
Active, not recruiting
Start date
January 31, 2009
Completion date
December 31, 2026
Enrollment
29 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia, myelodysplastic syndrome